Add Formweb to your mobile device
Approved Formulary
Search results for:
sacubitril-valsartan
sacubitril-valsartan
Brand names: Entresto
| Form | Strength |
|---|---|
| TABLET, ORAL | 24 mg-26 mg; 49 mg-51 mg; 97 mg-103 mg |
Display Angiotensin II Receptor Antagonists/Neprolysin Inhibitors Class:
243212
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | sacubitril-valsartan (Entresto) |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | RAS inhibitors (ACEIs ARBs, ARNIs, aliskiren) ⇄ Another RAS inhibitor or a potassium-sparing diuretic |
| Risk Rationale | Increased risk of hyperkalemia. |
| Recommendation | Avoid routinely using 2 or more RAS inhibitors, or a RAS inhibitor and potassium-sparing diuretic, concurrently in those with chronic kidney disease Stage 3a or higher. |
| Quality of evidence: Moderate, Strength of Recommendation: Strong | |
| Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics | |
|---|---|
| Medication: | sacubitril-valsartan (Entresto) |
| Key Potentially Inappropriate Drugs in Pediatrics (KIDs) List: Second Edition (Table 1) | |
| Drug | angiotensin receptor blockers |
| Risk/Rationale | Renal tubular dysgenesis |
| Recommendation | Caution in younger than 1 mo |
| Quality of evidence: Very low, Strength of Recommendation: Weak | |
Last updated: Sep. 25, 2025
- Black Box Warnings valsartan: Fetal Toxicity
- Black Box Warnings valsartan: Fetal Toxicity